Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
PCVX
$58.07
-1.34%
PCVX · Vaxcyte, Inc.
$58.07
-0.79 (-1.34%)
At close · Aug 14
Market Cap
$8.64B
Shares
148.81M
All earnings calls
Earnings call · FY2025 Q3
Vaxcyte, Inc. Q3 FY2025 Earnings Call
Vaxcyte, Inc. Q3 FY2025 Earnings Call
Forward guidance
1 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Diluted EPS
-$1.56
Net income
-$212.83M
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Nov 4, 2025.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Total costs for the dedicated manufacturing suite buildout
buildout expected to be completed by early 2026
|
up to $350M | — |
SEC filing · Item 2.02
8-K earnings release
Filed Nov 4, 2025 · complete as-filed document
SEC periodic report
10-Q report
Filed Nov 4, 2025 · complete as-filed document